nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltitrexed—Methotrexate—urinary bladder cancer	0.317	1	CrCtD
Raltitrexed—TYMS—urinary bladder cancer	0.194	1	CbGaD
Raltitrexed—FPGS—Methotrexate—urinary bladder cancer	0.0748	0.364	CbGbCtD
Raltitrexed—TYMS—Gemcitabine—urinary bladder cancer	0.0561	0.273	CbGbCtD
Raltitrexed—TYMS—Fluorouracil—urinary bladder cancer	0.048	0.234	CbGbCtD
Raltitrexed—Pemetrexed—Methotrexate—urinary bladder cancer	0.0419	0.2	CrCrCtD
Raltitrexed—Leucovorin—Methotrexate—urinary bladder cancer	0.0419	0.2	CrCrCtD
Raltitrexed—Tetrahydrofolic acid—Methotrexate—urinary bladder cancer	0.0419	0.2	CrCrCtD
Raltitrexed—Folic Acid—Methotrexate—urinary bladder cancer	0.0419	0.2	CrCrCtD
Raltitrexed—Pralatrexate—Methotrexate—urinary bladder cancer	0.0419	0.2	CrCrCtD
Raltitrexed—TYMS—Methotrexate—urinary bladder cancer	0.0265	0.129	CbGbCtD
Raltitrexed—FPGS—Metabolism of folate and pterines—SLC19A1—urinary bladder cancer	0.00555	0.188	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism of folate and pterines—MTHFR—urinary bladder cancer	0.00171	0.0577	CbGpPWpGaD
Raltitrexed—FPGS—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.00153	0.0517	CbGpPWpGaD
Raltitrexed—FPGS—prostate gland—urinary bladder cancer	0.0015	0.17	CbGeAlD
Raltitrexed—FPGS—seminal vesicle—urinary bladder cancer	0.00127	0.144	CbGeAlD
Raltitrexed—FPGS—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.00119	0.0404	CbGpPWpGaD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.00116	0.0393	CbGpPWpGaD
Raltitrexed—FPGS—urethra—urinary bladder cancer	0.001	0.114	CbGeAlD
Raltitrexed—TYMS—prostate gland—urinary bladder cancer	0.000982	0.111	CbGeAlD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000904	0.0306	CbGpPWpGaD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000881	0.0298	CbGpPWpGaD
Raltitrexed—FPGS—female reproductive system—urinary bladder cancer	0.000817	0.0927	CbGeAlD
Raltitrexed—Pralatrexate—SLC19A1—urinary bladder cancer	0.000779	0.36	CrCbGaD
Raltitrexed—TYMS—G1/S-Specific Transcription—RRM2—urinary bladder cancer	0.00074	0.025	CbGpPWpGaD
Raltitrexed—FPGS—vagina—urinary bladder cancer	0.000739	0.0839	CbGeAlD
Raltitrexed—TYMS—Pyrimidine metabolism—TYMP—urinary bladder cancer	0.000719	0.0243	CbGpPWpGaD
Raltitrexed—TYMS—smooth muscle tissue—urinary bladder cancer	0.000695	0.0789	CbGeAlD
Raltitrexed—FPGS—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.000691	0.0234	CbGpPWpGaD
Raltitrexed—FPGS—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000642	0.0217	CbGpPWpGaD
Raltitrexed—FPGS—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000604	0.0204	CbGpPWpGaD
Raltitrexed—TYMS—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.000558	0.0188	CbGpPWpGaD
Raltitrexed—TYMS—female reproductive system—urinary bladder cancer	0.000536	0.0608	CbGeAlD
Raltitrexed—TYMS—Podofilox—Etoposide—urinary bladder cancer	0.000494	0.713	CbGdCrCtD
Raltitrexed—TYMS—vagina—urinary bladder cancer	0.000485	0.055	CbGeAlD
Raltitrexed—FPGS—lymph node—urinary bladder cancer	0.000478	0.0542	CbGeAlD
Raltitrexed—TYMS—G1/S-Specific Transcription—CCNE1—urinary bladder cancer	0.000436	0.0147	CbGpPWpGaD
Raltitrexed—TYMS—E2F mediated regulation of DNA replication—RRM2—urinary bladder cancer	0.000435	0.0147	CbGpPWpGaD
Raltitrexed—TYMS—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.000435	0.0147	CbGpPWpGaD
Raltitrexed—Methotrexate—SLC19A1—urinary bladder cancer	0.000343	0.159	CrCbGaD
Raltitrexed—TYMS—lymph node—urinary bladder cancer	0.000313	0.0356	CbGeAlD
Raltitrexed—TYMS—Nucleotide metabolism—TYMP—urinary bladder cancer	0.00028	0.00947	CbGpPWpGaD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000278	0.0094	CbGpPWpGaD
Raltitrexed—TYMS—E2F mediated regulation of DNA replication—CCNE1—urinary bladder cancer	0.000257	0.00867	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—XRCC1—urinary bladder cancer	0.000256	0.00866	CbGpPWpGaD
Raltitrexed—TYMS—One Carbon Metabolism—MTHFR—urinary bladder cancer	0.000251	0.00848	CbGpPWpGaD
Raltitrexed—TYMS—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000234	0.00791	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—RRM2—urinary bladder cancer	0.000231	0.00779	CbGpPWpGaD
Raltitrexed—FPGS—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000229	0.00775	CbGpPWpGaD
Raltitrexed—Leucovorin—TYMS—urinary bladder cancer	0.000226	0.104	CrCbGaD
Raltitrexed—Pralatrexate—TYMS—urinary bladder cancer	0.000226	0.104	CrCbGaD
Raltitrexed—TYMS—Trans-sulfuration and one carbon metabolism—MTHFR—urinary bladder cancer	0.000226	0.00762	CbGpPWpGaD
Raltitrexed—TYMS—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.00022	0.00744	CbGpPWpGaD
Raltitrexed—TYMS—Nucleotide metabolism—RRM2—urinary bladder cancer	0.000219	0.00739	CbGpPWpGaD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	0.0002	0.00677	CbGpPWpGaD
Raltitrexed—TYMS—Azacitidine—Gemcitabine—urinary bladder cancer	0.000199	0.287	CbGdCrCtD
Raltitrexed—TYMS—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000184	0.00623	CbGpPWpGaD
Raltitrexed—Pemetrexed—TYMS—urinary bladder cancer	0.000181	0.0835	CrCbGaD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	0.000177	0.00599	CbGpPWpGaD
Raltitrexed—TYMS—E2F mediated regulation of DNA replication—RB1—urinary bladder cancer	0.000171	0.00577	CbGpPWpGaD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	0.00017	0.00576	CbGpPWpGaD
Raltitrexed—TYMS—G1/S Transition—RRM2—urinary bladder cancer	0.000167	0.00566	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—SMC1B—urinary bladder cancer	0.000145	0.00489	CbGpPWpGaD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—RRM2—urinary bladder cancer	0.000141	0.00477	CbGpPWpGaD
Raltitrexed—FPGS—Disease—GSTO2—urinary bladder cancer	0.000138	0.00465	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—CCNE1—urinary bladder cancer	0.000136	0.00459	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.00013	0.00438	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—GSTZ1—urinary bladder cancer	0.000122	0.00411	CbGpPWpGaD
Raltitrexed—TYMS—Nucleotide metabolism—GPX1—urinary bladder cancer	0.00012	0.00405	CbGpPWpGaD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	0.000118	0.00399	CbGpPWpGaD
Raltitrexed—Folic Acid—MTHFR—urinary bladder cancer	0.000116	0.0535	CrCbGaD
Raltitrexed—Tetrahydrofolic acid—MTHFR—urinary bladder cancer	0.000116	0.0535	CrCbGaD
Raltitrexed—FPGS—Metabolism—GSTO2—urinary bladder cancer	0.000115	0.00389	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—NAT1—urinary bladder cancer	0.000115	0.00389	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—PLAU—urinary bladder cancer	0.00011	0.00372	CbGpPWpGaD
Raltitrexed—FPGS—Disease—SLC19A1—urinary bladder cancer	0.000107	0.00362	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—UGT2B7—urinary bladder cancer	0.000105	0.00356	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—ATM—urinary bladder cancer	0.000105	0.00353	CbGpPWpGaD
Raltitrexed—FPGS—Disease—PRSS3—urinary bladder cancer	0.000104	0.00352	CbGpPWpGaD
Raltitrexed—Methotrexate—TYMS—urinary bladder cancer	9.97e-05	0.046	CrCbGaD
Raltitrexed—FPGS—Disease—HDAC4—urinary bladder cancer	9.95e-05	0.00336	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	9.89e-05	0.00334	CbGpPWpGaD
Raltitrexed—TYMS—G1/S Transition—CCNE1—urinary bladder cancer	9.86e-05	0.00333	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	9.83e-05	0.00332	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—CYP4B1—urinary bladder cancer	9.49e-05	0.00321	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—CREBBP—urinary bladder cancer	9.08e-05	0.00307	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—RB1—urinary bladder cancer	9.05e-05	0.00306	CbGpPWpGaD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	9.05e-05	0.00306	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—SLC19A1—urinary bladder cancer	8.96e-05	0.00303	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—PRSS3—urinary bladder cancer	8.73e-05	0.00295	CbGpPWpGaD
Raltitrexed—Cough—Thiotepa—urinary bladder cancer	8.68e-05	0.00261	CcSEcCtD
Raltitrexed—Arrhythmia—Gemcitabine—urinary bladder cancer	8.59e-05	0.00258	CcSEcCtD
Raltitrexed—Sepsis—Methotrexate—urinary bladder cancer	8.5e-05	0.00255	CcSEcCtD
Raltitrexed—Alopecia—Gemcitabine—urinary bladder cancer	8.5e-05	0.00255	CcSEcCtD
Raltitrexed—Arthralgia—Thiotepa—urinary bladder cancer	8.47e-05	0.00254	CcSEcCtD
Raltitrexed—Arrhythmia—Fluorouracil—urinary bladder cancer	8.45e-05	0.00254	CcSEcCtD
Raltitrexed—TYMS—Fluoropyrimidine Activity—TP53—urinary bladder cancer	8.36e-05	0.00282	CbGpPWpGaD
Raltitrexed—Alopecia—Fluorouracil—urinary bladder cancer	8.36e-05	0.00251	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	8.31e-05	0.00281	CbGpPWpGaD
Raltitrexed—Mouth ulceration—Epirubicin—urinary bladder cancer	8.29e-05	0.00249	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	8.29e-05	0.0028	CbGpPWpGaD
Raltitrexed—Influenza like illness—Doxorubicin—urinary bladder cancer	8.24e-05	0.00247	CcSEcCtD
Raltitrexed—Skin exfoliation—Doxorubicin—urinary bladder cancer	8.1e-05	0.00243	CcSEcCtD
Raltitrexed—Infection—Thiotepa—urinary bladder cancer	8.07e-05	0.00242	CcSEcCtD
Raltitrexed—Hypertonia—Epirubicin—urinary bladder cancer	8.04e-05	0.00241	CcSEcCtD
Raltitrexed—Arrhythmia—Cisplatin—urinary bladder cancer	8.01e-05	0.0024	CcSEcCtD
Raltitrexed—TYMS—E2F transcription factor network—CDKN2A—urinary bladder cancer	7.96e-05	0.00269	CbGpPWpGaD
Raltitrexed—Sepsis—Epirubicin—urinary bladder cancer	7.95e-05	0.00239	CcSEcCtD
Raltitrexed—Thrombocytopenia—Thiotepa—urinary bladder cancer	7.95e-05	0.00239	CcSEcCtD
Raltitrexed—Methotrexate—MTHFR—urinary bladder cancer	7.93e-05	0.0366	CrCbGaD
Raltitrexed—Alopecia—Cisplatin—urinary bladder cancer	7.92e-05	0.00238	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	7.92e-05	0.00268	CbGpPWpGaD
Raltitrexed—Hepatic failure—Methotrexate—urinary bladder cancer	7.91e-05	0.00237	CcSEcCtD
Raltitrexed—FPGS—Disease—LIG1—urinary bladder cancer	7.9e-05	0.00267	CbGpPWpGaD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	7.87e-05	0.00266	CbGpPWpGaD
Raltitrexed—Ill-defined disorder—Gemcitabine—urinary bladder cancer	7.77e-05	0.00233	CcSEcCtD
Raltitrexed—Anorexia—Thiotepa—urinary bladder cancer	7.74e-05	0.00232	CcSEcCtD
Raltitrexed—Anaemia—Gemcitabine—urinary bladder cancer	7.74e-05	0.00232	CcSEcCtD
Raltitrexed—Mouth ulceration—Doxorubicin—urinary bladder cancer	7.67e-05	0.0023	CcSEcCtD
Raltitrexed—Anaemia—Fluorouracil—urinary bladder cancer	7.61e-05	0.00228	CcSEcCtD
Raltitrexed—Malaise—Gemcitabine—urinary bladder cancer	7.55e-05	0.00227	CcSEcCtD
Raltitrexed—Leukopenia—Gemcitabine—urinary bladder cancer	7.49e-05	0.00225	CcSEcCtD
Raltitrexed—Hypertonia—Doxorubicin—urinary bladder cancer	7.43e-05	0.00223	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—ESPL1—urinary bladder cancer	7.41e-05	0.0025	CbGpPWpGaD
Raltitrexed—Hepatic failure—Epirubicin—urinary bladder cancer	7.4e-05	0.00222	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	7.4e-05	0.00222	CcSEcCtD
Raltitrexed—Leukopenia—Fluorouracil—urinary bladder cancer	7.37e-05	0.00221	CcSEcCtD
Raltitrexed—Sepsis—Doxorubicin—urinary bladder cancer	7.36e-05	0.00221	CcSEcCtD
Raltitrexed—Cardiac failure congestive—Epirubicin—urinary bladder cancer	7.34e-05	0.0022	CcSEcCtD
Raltitrexed—Cough—Gemcitabine—urinary bladder cancer	7.31e-05	0.00219	CcSEcCtD
Raltitrexed—Alopecia—Etoposide—urinary bladder cancer	7.26e-05	0.00218	CcSEcCtD
Raltitrexed—Ill-defined disorder—Cisplatin—urinary bladder cancer	7.24e-05	0.00217	CcSEcCtD
Raltitrexed—Anaemia—Cisplatin—urinary bladder cancer	7.21e-05	0.00216	CcSEcCtD
Raltitrexed—Dyspepsia—Thiotepa—urinary bladder cancer	7.15e-05	0.00215	CcSEcCtD
Raltitrexed—Arthralgia—Gemcitabine—urinary bladder cancer	7.13e-05	0.00214	CcSEcCtD
Raltitrexed—Decreased appetite—Thiotepa—urinary bladder cancer	7.06e-05	0.00212	CcSEcCtD
Raltitrexed—Discomfort—Gemcitabine—urinary bladder cancer	7.04e-05	0.00211	CcSEcCtD
Raltitrexed—Malaise—Cisplatin—urinary bladder cancer	7.04e-05	0.00211	CcSEcCtD
Raltitrexed—Dysgeusia—Etoposide—urinary bladder cancer	7e-05	0.0021	CcSEcCtD
Raltitrexed—Renal impairment—Epirubicin—urinary bladder cancer	6.99e-05	0.0021	CcSEcCtD
Raltitrexed—Leukopenia—Cisplatin—urinary bladder cancer	6.98e-05	0.0021	CcSEcCtD
Raltitrexed—FPGS—Metabolism—TYMP—urinary bladder cancer	6.98e-05	0.00236	CbGpPWpGaD
Raltitrexed—Pain—Thiotepa—urinary bladder cancer	6.95e-05	0.00208	CcSEcCtD
Raltitrexed—Constipation—Thiotepa—urinary bladder cancer	6.95e-05	0.00208	CcSEcCtD
Raltitrexed—Discomfort—Fluorouracil—urinary bladder cancer	6.92e-05	0.00208	CcSEcCtD
Raltitrexed—Hepatic failure—Doxorubicin—urinary bladder cancer	6.85e-05	0.00206	CcSEcCtD
Raltitrexed—Oedema—Gemcitabine—urinary bladder cancer	6.83e-05	0.00205	CcSEcCtD
Raltitrexed—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	6.79e-05	0.00204	CcSEcCtD
Raltitrexed—Infection—Gemcitabine—urinary bladder cancer	6.79e-05	0.00204	CcSEcCtD
Raltitrexed—Oedema—Fluorouracil—urinary bladder cancer	6.72e-05	0.00202	CcSEcCtD
Raltitrexed—Feeling abnormal—Thiotepa—urinary bladder cancer	6.69e-05	0.00201	CcSEcCtD
Raltitrexed—Thrombocytopenia—Gemcitabine—urinary bladder cancer	6.69e-05	0.00201	CcSEcCtD
Raltitrexed—Infection—Fluorouracil—urinary bladder cancer	6.67e-05	0.002	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Thiotepa—urinary bladder cancer	6.64e-05	0.00199	CcSEcCtD
Raltitrexed—Ill-defined disorder—Etoposide—urinary bladder cancer	6.63e-05	0.00199	CcSEcCtD
Raltitrexed—Anaemia—Etoposide—urinary bladder cancer	6.61e-05	0.00198	CcSEcCtD
Raltitrexed—Hyperhidrosis—Gemcitabine—urinary bladder cancer	6.61e-05	0.00198	CcSEcCtD
Raltitrexed—Thrombocytopenia—Fluorouracil—urinary bladder cancer	6.58e-05	0.00197	CcSEcCtD
Raltitrexed—TYMS—G1/S Transition—RB1—urinary bladder cancer	6.57e-05	0.00222	CbGpPWpGaD
Raltitrexed—Discomfort—Cisplatin—urinary bladder cancer	6.56e-05	0.00197	CcSEcCtD
Raltitrexed—Anorexia—Gemcitabine—urinary bladder cancer	6.51e-05	0.00195	CcSEcCtD
Raltitrexed—TYMS—E2F transcription factor network—CDKN1A—urinary bladder cancer	6.5e-05	0.0022	CbGpPWpGaD
Raltitrexed—Renal impairment—Doxorubicin—urinary bladder cancer	6.47e-05	0.00194	CcSEcCtD
Raltitrexed—Malaise—Etoposide—urinary bladder cancer	6.45e-05	0.00193	CcSEcCtD
Raltitrexed—Body temperature increased—Thiotepa—urinary bladder cancer	6.42e-05	0.00193	CcSEcCtD
Raltitrexed—Abdominal pain—Thiotepa—urinary bladder cancer	6.42e-05	0.00193	CcSEcCtD
Raltitrexed—Anorexia—Fluorouracil—urinary bladder cancer	6.4e-05	0.00192	CcSEcCtD
Raltitrexed—Leukopenia—Etoposide—urinary bladder cancer	6.4e-05	0.00192	CcSEcCtD
Raltitrexed—Oedema—Cisplatin—urinary bladder cancer	6.37e-05	0.00191	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	6.36e-05	0.00215	CbGpPWpGaD
Raltitrexed—Infection—Cisplatin—urinary bladder cancer	6.33e-05	0.0019	CcSEcCtD
Raltitrexed—FPGS—Metabolism—NAT2—urinary bladder cancer	6.31e-05	0.00213	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	6.3e-05	0.00213	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	6.28e-05	0.00212	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	6.28e-05	0.00212	CbGpPWpGaD
Raltitrexed—Cough—Etoposide—urinary bladder cancer	6.24e-05	0.00187	CcSEcCtD
Raltitrexed—Thrombocytopenia—Cisplatin—urinary bladder cancer	6.24e-05	0.00187	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	6.23e-05	0.00187	CcSEcCtD
Raltitrexed—Dehydration—Epirubicin—urinary bladder cancer	6.19e-05	0.00186	CcSEcCtD
Raltitrexed—TYMS—E2F transcription factor network—EP300—urinary bladder cancer	6.19e-05	0.00209	CbGpPWpGaD
Raltitrexed—Hyperhidrosis—Cisplatin—urinary bladder cancer	6.16e-05	0.00185	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	6.12e-05	0.00184	CcSEcCtD
Raltitrexed—Anorexia—Cisplatin—urinary bladder cancer	6.07e-05	0.00182	CcSEcCtD
Raltitrexed—FPGS—Disease—ENO2—urinary bladder cancer	6.03e-05	0.00204	CbGpPWpGaD
Raltitrexed—Discomfort—Etoposide—urinary bladder cancer	6.01e-05	0.0018	CcSEcCtD
Raltitrexed—Decreased appetite—Gemcitabine—urinary bladder cancer	5.94e-05	0.00178	CcSEcCtD
Raltitrexed—Dyspepsia—Fluorouracil—urinary bladder cancer	5.91e-05	0.00177	CcSEcCtD
Raltitrexed—TYMS—Circadian rythm related genes—NCOR1—urinary bladder cancer	5.87e-05	0.00198	CbGpPWpGaD
Raltitrexed—Pain—Gemcitabine—urinary bladder cancer	5.84e-05	0.00175	CcSEcCtD
Raltitrexed—Constipation—Gemcitabine—urinary bladder cancer	5.84e-05	0.00175	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	5.84e-05	0.00197	CbGpPWpGaD
Raltitrexed—Decreased appetite—Fluorouracil—urinary bladder cancer	5.84e-05	0.00175	CcSEcCtD
Raltitrexed—Asthenia—Thiotepa—urinary bladder cancer	5.83e-05	0.00175	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	5.8e-05	0.00174	CcSEcCtD
Raltitrexed—Infection—Etoposide—urinary bladder cancer	5.8e-05	0.00174	CcSEcCtD
Raltitrexed—Neutropenia—Methotrexate—urinary bladder cancer	5.75e-05	0.00172	CcSEcCtD
Raltitrexed—Pruritus—Thiotepa—urinary bladder cancer	5.75e-05	0.00172	CcSEcCtD
Raltitrexed—Pain—Fluorouracil—urinary bladder cancer	5.74e-05	0.00172	CcSEcCtD
Raltitrexed—Dehydration—Doxorubicin—urinary bladder cancer	5.73e-05	0.00172	CcSEcCtD
Raltitrexed—FPGS—Disease—RBX1—urinary bladder cancer	5.71e-05	0.00193	CbGpPWpGaD
Raltitrexed—Thrombocytopenia—Etoposide—urinary bladder cancer	5.71e-05	0.00171	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	5.65e-05	0.00191	CbGpPWpGaD
Raltitrexed—Hyperhidrosis—Etoposide—urinary bladder cancer	5.64e-05	0.00169	CcSEcCtD
Raltitrexed—Feeling abnormal—Gemcitabine—urinary bladder cancer	5.63e-05	0.00169	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—STAG2—urinary bladder cancer	5.62e-05	0.0019	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—LIG1—urinary bladder cancer	5.62e-05	0.0019	CbGpPWpGaD
Raltitrexed—Anorexia—Etoposide—urinary bladder cancer	5.56e-05	0.00167	CcSEcCtD
Raltitrexed—Diarrhoea—Thiotepa—urinary bladder cancer	5.56e-05	0.00167	CcSEcCtD
Raltitrexed—Decreased appetite—Cisplatin—urinary bladder cancer	5.54e-05	0.00166	CcSEcCtD
Raltitrexed—Feeling abnormal—Fluorouracil—urinary bladder cancer	5.54e-05	0.00166	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	5.53e-05	0.00187	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5.48e-05	0.00185	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—RRM2—urinary bladder cancer	5.45e-05	0.00184	CbGpPWpGaD
Raltitrexed—Pain—Cisplatin—urinary bladder cancer	5.45e-05	0.00163	CcSEcCtD
Raltitrexed—Body temperature increased—Gemcitabine—urinary bladder cancer	5.4e-05	0.00162	CcSEcCtD
Raltitrexed—TYMS—E2F transcription factor network—MYC—urinary bladder cancer	5.39e-05	0.00182	CbGpPWpGaD
Raltitrexed—Renal failure—Methotrexate—urinary bladder cancer	5.39e-05	0.00162	CcSEcCtD
Raltitrexed—Neutropenia—Epirubicin—urinary bladder cancer	5.38e-05	0.00161	CcSEcCtD
Raltitrexed—Stomatitis—Methotrexate—urinary bladder cancer	5.34e-05	0.0016	CcSEcCtD
Raltitrexed—Conjunctivitis—Methotrexate—urinary bladder cancer	5.33e-05	0.0016	CcSEcCtD
Raltitrexed—Body temperature increased—Fluorouracil—urinary bladder cancer	5.31e-05	0.00159	CcSEcCtD
Raltitrexed—TYMS—Circadian rythm related genes—FAS—urinary bladder cancer	5.26e-05	0.00178	CbGpPWpGaD
Raltitrexed—Sweating—Methotrexate—urinary bladder cancer	5.25e-05	0.00158	CcSEcCtD
Raltitrexed—Feeling abnormal—Cisplatin—urinary bladder cancer	5.25e-05	0.00158	CcSEcCtD
Raltitrexed—Weight decreased—Epirubicin—urinary bladder cancer	5.2e-05	0.00156	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	5.17e-05	0.00175	CbGpPWpGaD
Raltitrexed—Vomiting—Thiotepa—urinary bladder cancer	5.16e-05	0.00155	CcSEcCtD
Raltitrexed—Rash—Thiotepa—urinary bladder cancer	5.12e-05	0.00154	CcSEcCtD
Raltitrexed—Dermatitis—Thiotepa—urinary bladder cancer	5.12e-05	0.00154	CcSEcCtD
Raltitrexed—FPGS—Disease—JAG1—urinary bladder cancer	5.11e-05	0.00173	CbGpPWpGaD
Raltitrexed—Headache—Thiotepa—urinary bladder cancer	5.09e-05	0.00153	CcSEcCtD
Raltitrexed—Decreased appetite—Etoposide—urinary bladder cancer	5.07e-05	0.00152	CcSEcCtD
Raltitrexed—FPGS—Metabolism—ENO2—urinary bladder cancer	5.05e-05	0.00171	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—HPGDS—urinary bladder cancer	5.05e-05	0.00171	CbGpPWpGaD
Raltitrexed—Renal failure—Epirubicin—urinary bladder cancer	5.04e-05	0.00151	CcSEcCtD
Raltitrexed—Body temperature increased—Cisplatin—urinary bladder cancer	5.03e-05	0.00151	CcSEcCtD
Raltitrexed—Stomatitis—Epirubicin—urinary bladder cancer	5e-05	0.0015	CcSEcCtD
Raltitrexed—Pain—Etoposide—urinary bladder cancer	4.99e-05	0.0015	CcSEcCtD
Raltitrexed—Constipation—Etoposide—urinary bladder cancer	4.99e-05	0.0015	CcSEcCtD
Raltitrexed—Conjunctivitis—Epirubicin—urinary bladder cancer	4.98e-05	0.0015	CcSEcCtD
Raltitrexed—Neutropenia—Doxorubicin—urinary bladder cancer	4.98e-05	0.00149	CcSEcCtD
Raltitrexed—Sweating—Epirubicin—urinary bladder cancer	4.92e-05	0.00148	CcSEcCtD
Raltitrexed—Asthenia—Gemcitabine—urinary bladder cancer	4.9e-05	0.00147	CcSEcCtD
Raltitrexed—FPGS—Metabolism—GSTT1—urinary bladder cancer	4.9e-05	0.00165	CbGpPWpGaD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	4.86e-05	0.00164	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.84e-05	0.00164	CbGpPWpGaD
Raltitrexed—Pruritus—Gemcitabine—urinary bladder cancer	4.83e-05	0.00145	CcSEcCtD
Raltitrexed—Nausea—Thiotepa—urinary bladder cancer	4.82e-05	0.00145	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.82e-05	0.00163	CbGpPWpGaD
Raltitrexed—Weight decreased—Doxorubicin—urinary bladder cancer	4.81e-05	0.00144	CcSEcCtD
Raltitrexed—Feeling abnormal—Etoposide—urinary bladder cancer	4.81e-05	0.00144	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.8e-05	0.00162	CbGpPWpGaD
Raltitrexed—Gastrointestinal pain—Etoposide—urinary bladder cancer	4.77e-05	0.00143	CcSEcCtD
Raltitrexed—Pruritus—Fluorouracil—urinary bladder cancer	4.75e-05	0.00143	CcSEcCtD
Raltitrexed—TYMS—G1/S Transition—CDKN1A—urinary bladder cancer	4.72e-05	0.00159	CbGpPWpGaD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	4.69e-05	0.00158	CbGpPWpGaD
Raltitrexed—Diarrhoea—Gemcitabine—urinary bladder cancer	4.67e-05	0.0014	CcSEcCtD
Raltitrexed—Renal failure—Doxorubicin—urinary bladder cancer	4.66e-05	0.0014	CcSEcCtD
Raltitrexed—TYMS—Circadian rythm related genes—CDK4—urinary bladder cancer	4.63e-05	0.00156	CbGpPWpGaD
Raltitrexed—Stomatitis—Doxorubicin—urinary bladder cancer	4.62e-05	0.00139	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—RRM2—urinary bladder cancer	4.62e-05	0.00156	CbGpPWpGaD
Raltitrexed—Body temperature increased—Etoposide—urinary bladder cancer	4.61e-05	0.00138	CcSEcCtD
Raltitrexed—Abdominal pain—Etoposide—urinary bladder cancer	4.61e-05	0.00138	CcSEcCtD
Raltitrexed—Conjunctivitis—Doxorubicin—urinary bladder cancer	4.61e-05	0.00138	CcSEcCtD
Raltitrexed—Diarrhoea—Fluorouracil—urinary bladder cancer	4.6e-05	0.00138	CcSEcCtD
Raltitrexed—Asthenia—Cisplatin—urinary bladder cancer	4.57e-05	0.00137	CcSEcCtD
Raltitrexed—Sweating—Doxorubicin—urinary bladder cancer	4.55e-05	0.00137	CcSEcCtD
Raltitrexed—TYMS—Metabolism—GSTZ1—urinary bladder cancer	4.43e-05	0.0015	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	4.4e-05	0.00149	CbGpPWpGaD
Raltitrexed—Diarrhoea—Cisplatin—urinary bladder cancer	4.36e-05	0.00131	CcSEcCtD
Raltitrexed—Alopecia—Methotrexate—urinary bladder cancer	4.35e-05	0.0013	CcSEcCtD
Raltitrexed—Vomiting—Gemcitabine—urinary bladder cancer	4.34e-05	0.0013	CcSEcCtD
Raltitrexed—Rash—Gemcitabine—urinary bladder cancer	4.31e-05	0.00129	CcSEcCtD
Raltitrexed—Dermatitis—Gemcitabine—urinary bladder cancer	4.3e-05	0.00129	CcSEcCtD
Raltitrexed—Headache—Gemcitabine—urinary bladder cancer	4.28e-05	0.00128	CcSEcCtD
Raltitrexed—Vomiting—Fluorouracil—urinary bladder cancer	4.27e-05	0.00128	CcSEcCtD
Raltitrexed—Rash—Fluorouracil—urinary bladder cancer	4.24e-05	0.00127	CcSEcCtD
Raltitrexed—Dermatitis—Fluorouracil—urinary bladder cancer	4.23e-05	0.00127	CcSEcCtD
Raltitrexed—Headache—Fluorouracil—urinary bladder cancer	4.21e-05	0.00126	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.21e-05	0.00142	CbGpPWpGaD
Raltitrexed—TYMS—Circadian rythm related genes—PPARG—urinary bladder cancer	4.21e-05	0.00142	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—NAT1—urinary bladder cancer	4.2e-05	0.00142	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GSTO2—urinary bladder cancer	4.2e-05	0.00142	CbGpPWpGaD
Raltitrexed—Dysgeusia—Methotrexate—urinary bladder cancer	4.19e-05	0.00126	CcSEcCtD
Raltitrexed—Asthenia—Etoposide—urinary bladder cancer	4.19e-05	0.00126	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.16e-05	0.0014	CbGpPWpGaD
Raltitrexed—Pruritus—Etoposide—urinary bladder cancer	4.13e-05	0.00124	CcSEcCtD
Raltitrexed—Arrhythmia—Epirubicin—urinary bladder cancer	4.11e-05	0.00123	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	4.11e-05	0.00139	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—NQO1—urinary bladder cancer	4.07e-05	0.00138	CbGpPWpGaD
Raltitrexed—Alopecia—Epirubicin—urinary bladder cancer	4.07e-05	0.00122	CcSEcCtD
Raltitrexed—Nausea—Gemcitabine—urinary bladder cancer	4.06e-05	0.00122	CcSEcCtD
Raltitrexed—Vomiting—Cisplatin—urinary bladder cancer	4.05e-05	0.00122	CcSEcCtD
Raltitrexed—Rash—Cisplatin—urinary bladder cancer	4.02e-05	0.00121	CcSEcCtD
Raltitrexed—Dermatitis—Cisplatin—urinary bladder cancer	4.01e-05	0.0012	CcSEcCtD
Raltitrexed—Diarrhoea—Etoposide—urinary bladder cancer	3.99e-05	0.0012	CcSEcCtD
Raltitrexed—Nausea—Fluorouracil—urinary bladder cancer	3.99e-05	0.0012	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	3.98e-05	0.00134	CbGpPWpGaD
Raltitrexed—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.97e-05	0.00119	CcSEcCtD
Raltitrexed—Anaemia—Methotrexate—urinary bladder cancer	3.96e-05	0.00119	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—SMC1A—urinary bladder cancer	3.93e-05	0.00133	CbGpPWpGaD
Raltitrexed—Dysgeusia—Epirubicin—urinary bladder cancer	3.92e-05	0.00118	CcSEcCtD
Raltitrexed—TYMS—G1/S Transition—MYC—urinary bladder cancer	3.91e-05	0.00132	CbGpPWpGaD
Raltitrexed—Malaise—Methotrexate—urinary bladder cancer	3.86e-05	0.00116	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	3.85e-05	0.0013	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—UGT2B7—urinary bladder cancer	3.84e-05	0.0013	CbGpPWpGaD
Raltitrexed—Leukopenia—Methotrexate—urinary bladder cancer	3.83e-05	0.00115	CcSEcCtD
Raltitrexed—Arrhythmia—Doxorubicin—urinary bladder cancer	3.81e-05	0.00114	CcSEcCtD
Raltitrexed—Nausea—Cisplatin—urinary bladder cancer	3.78e-05	0.00114	CcSEcCtD
Raltitrexed—Alopecia—Doxorubicin—urinary bladder cancer	3.76e-05	0.00113	CcSEcCtD
Raltitrexed—Cough—Methotrexate—urinary bladder cancer	3.74e-05	0.00112	CcSEcCtD
Raltitrexed—FPGS—Disease—NCOR1—urinary bladder cancer	3.72e-05	0.00126	CbGpPWpGaD
Raltitrexed—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.72e-05	0.00112	CcSEcCtD
Raltitrexed—Vomiting—Etoposide—urinary bladder cancer	3.71e-05	0.00111	CcSEcCtD
Raltitrexed—Anaemia—Epirubicin—urinary bladder cancer	3.7e-05	0.00111	CcSEcCtD
Raltitrexed—Rash—Etoposide—urinary bladder cancer	3.68e-05	0.0011	CcSEcCtD
Raltitrexed—Dermatitis—Etoposide—urinary bladder cancer	3.68e-05	0.0011	CcSEcCtD
Raltitrexed—Headache—Etoposide—urinary bladder cancer	3.66e-05	0.0011	CcSEcCtD
Raltitrexed—Arthralgia—Methotrexate—urinary bladder cancer	3.65e-05	0.00109	CcSEcCtD
Raltitrexed—Dysgeusia—Doxorubicin—urinary bladder cancer	3.63e-05	0.00109	CcSEcCtD
Raltitrexed—Malaise—Epirubicin—urinary bladder cancer	3.61e-05	0.00108	CcSEcCtD
Raltitrexed—Discomfort—Methotrexate—urinary bladder cancer	3.6e-05	0.00108	CcSEcCtD
Raltitrexed—Leukopenia—Epirubicin—urinary bladder cancer	3.59e-05	0.00108	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.52e-05	0.00119	CbGpPWpGaD
Raltitrexed—FPGS—Disease—ERCC2—urinary bladder cancer	3.5e-05	0.00118	CbGpPWpGaD
Raltitrexed—Cough—Epirubicin—urinary bladder cancer	3.5e-05	0.00105	CcSEcCtD
Raltitrexed—Infection—Methotrexate—urinary bladder cancer	3.47e-05	0.00104	CcSEcCtD
Raltitrexed—Nausea—Etoposide—urinary bladder cancer	3.47e-05	0.00104	CcSEcCtD
Raltitrexed—TYMS—Metabolism—CYP4B1—urinary bladder cancer	3.46e-05	0.00117	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.45e-05	0.00116	CbGpPWpGaD
Raltitrexed—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.44e-05	0.00103	CcSEcCtD
Raltitrexed—Anaemia—Doxorubicin—urinary bladder cancer	3.43e-05	0.00103	CcSEcCtD
Raltitrexed—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.42e-05	0.00103	CcSEcCtD
Raltitrexed—Arthralgia—Epirubicin—urinary bladder cancer	3.41e-05	0.00102	CcSEcCtD
Raltitrexed—FPGS—Metabolism—GSTP1—urinary bladder cancer	3.39e-05	0.00115	CbGpPWpGaD
Raltitrexed—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.38e-05	0.00101	CcSEcCtD
Raltitrexed—Discomfort—Epirubicin—urinary bladder cancer	3.37e-05	0.00101	CcSEcCtD
Raltitrexed—Malaise—Doxorubicin—urinary bladder cancer	3.34e-05	0.001	CcSEcCtD
Raltitrexed—Anorexia—Methotrexate—urinary bladder cancer	3.33e-05	0.001	CcSEcCtD
Raltitrexed—Leukopenia—Doxorubicin—urinary bladder cancer	3.32e-05	0.000996	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	3.3e-05	0.00111	CbGpPWpGaD
Raltitrexed—FPGS—Disease—MTHFR—urinary bladder cancer	3.29e-05	0.00111	CbGpPWpGaD
Raltitrexed—FPGS—Disease—TERT—urinary bladder cancer	3.28e-05	0.00111	CbGpPWpGaD
Raltitrexed—Oedema—Epirubicin—urinary bladder cancer	3.27e-05	0.000982	CcSEcCtD
Raltitrexed—TYMS—Metabolism—SLC19A1—urinary bladder cancer	3.27e-05	0.0011	CbGpPWpGaD
Raltitrexed—Infection—Epirubicin—urinary bladder cancer	3.25e-05	0.000975	CcSEcCtD
Raltitrexed—Cough—Doxorubicin—urinary bladder cancer	3.24e-05	0.000971	CcSEcCtD
Raltitrexed—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.2e-05	0.000961	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.18e-05	0.000956	CcSEcCtD
Raltitrexed—TYMS—Metabolism—PRSS3—urinary bladder cancer	3.18e-05	0.00108	CbGpPWpGaD
Raltitrexed—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.16e-05	0.000949	CcSEcCtD
Raltitrexed—Arthralgia—Doxorubicin—urinary bladder cancer	3.16e-05	0.000947	CcSEcCtD
Raltitrexed—FPGS—Metabolism—TYMS—urinary bladder cancer	3.16e-05	0.00107	CbGpPWpGaD
Raltitrexed—Discomfort—Doxorubicin—urinary bladder cancer	3.12e-05	0.000936	CcSEcCtD
Raltitrexed—FPGS—Metabolism—GSTM1—urinary bladder cancer	3.12e-05	0.00105	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—NCOR1—urinary bladder cancer	3.12e-05	0.00105	CbGpPWpGaD
Raltitrexed—Anorexia—Epirubicin—urinary bladder cancer	3.12e-05	0.000936	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.11e-05	0.00105	CbGpPWpGaD
Raltitrexed—Dyspepsia—Methotrexate—urinary bladder cancer	3.08e-05	0.000923	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	3.05e-05	0.00103	CbGpPWpGaD
Raltitrexed—Decreased appetite—Methotrexate—urinary bladder cancer	3.04e-05	0.000912	CcSEcCtD
Raltitrexed—Oedema—Doxorubicin—urinary bladder cancer	3.03e-05	0.000908	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.01e-05	0.00102	CbGpPWpGaD
Raltitrexed—FPGS—Disease—FGFR3—urinary bladder cancer	3.01e-05	0.00102	CbGpPWpGaD
Raltitrexed—Infection—Doxorubicin—urinary bladder cancer	3.01e-05	0.000902	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.01e-05	0.00102	CbGpPWpGaD
Raltitrexed—Pain—Methotrexate—urinary bladder cancer	2.99e-05	0.000897	CcSEcCtD
Raltitrexed—FPGS—Metabolism—GPX1—urinary bladder cancer	2.99e-05	0.00101	CbGpPWpGaD
Raltitrexed—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.98e-05	0.000894	CcSEcCtD
Raltitrexed—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.96e-05	0.000889	CcSEcCtD
Raltitrexed—FPGS—Metabolism—ERCC2—urinary bladder cancer	2.93e-05	0.000991	CbGpPWpGaD
Raltitrexed—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.93e-05	0.000878	CcSEcCtD
Raltitrexed—TYMS—Circadian rythm related genes—PTEN—urinary bladder cancer	2.89e-05	0.000975	CbGpPWpGaD
Raltitrexed—Anorexia—Doxorubicin—urinary bladder cancer	2.88e-05	0.000866	CcSEcCtD
Raltitrexed—Feeling abnormal—Methotrexate—urinary bladder cancer	2.88e-05	0.000864	CcSEcCtD
Raltitrexed—Dyspepsia—Epirubicin—urinary bladder cancer	2.88e-05	0.000864	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.87e-05	0.000969	CbGpPWpGaD
Raltitrexed—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.86e-05	0.000858	CcSEcCtD
Raltitrexed—Decreased appetite—Epirubicin—urinary bladder cancer	2.84e-05	0.000853	CcSEcCtD
Raltitrexed—Constipation—Epirubicin—urinary bladder cancer	2.8e-05	0.000839	CcSEcCtD
Raltitrexed—Pain—Epirubicin—urinary bladder cancer	2.8e-05	0.000839	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.79e-05	0.000942	CbGpPWpGaD
Raltitrexed—Body temperature increased—Methotrexate—urinary bladder cancer	2.76e-05	0.000829	CcSEcCtD
Raltitrexed—Abdominal pain—Methotrexate—urinary bladder cancer	2.76e-05	0.000829	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.76e-05	0.000827	CcSEcCtD
Raltitrexed—FPGS—Metabolism—MTHFR—urinary bladder cancer	2.76e-05	0.000931	CbGpPWpGaD
Raltitrexed—TYMS—Circadian rythm related genes—EP300—urinary bladder cancer	2.75e-05	0.00093	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CCNE1—urinary bladder cancer	2.73e-05	0.000921	CbGpPWpGaD
Raltitrexed—Feeling abnormal—Epirubicin—urinary bladder cancer	2.7e-05	0.000809	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.67e-05	0.000803	CcSEcCtD
Raltitrexed—Dyspepsia—Doxorubicin—urinary bladder cancer	2.66e-05	0.000799	CcSEcCtD
Raltitrexed—Decreased appetite—Doxorubicin—urinary bladder cancer	2.63e-05	0.00079	CcSEcCtD
Raltitrexed—Pain—Doxorubicin—urinary bladder cancer	2.59e-05	0.000777	CcSEcCtD
Raltitrexed—Constipation—Doxorubicin—urinary bladder cancer	2.59e-05	0.000777	CcSEcCtD
Raltitrexed—Abdominal pain—Epirubicin—urinary bladder cancer	2.59e-05	0.000776	CcSEcCtD
Raltitrexed—Body temperature increased—Epirubicin—urinary bladder cancer	2.59e-05	0.000776	CcSEcCtD
Raltitrexed—FPGS—Disease—CREBBP—urinary bladder cancer	2.56e-05	0.000866	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—TYMP—urinary bladder cancer	2.55e-05	0.00086	CbGpPWpGaD
Raltitrexed—Asthenia—Methotrexate—urinary bladder cancer	2.51e-05	0.000753	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.5e-05	0.000844	CbGpPWpGaD
Raltitrexed—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.49e-05	0.000748	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.47e-05	0.000743	CcSEcCtD
Raltitrexed—Pruritus—Methotrexate—urinary bladder cancer	2.47e-05	0.000742	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.44e-05	0.000826	CbGpPWpGaD
Raltitrexed—Body temperature increased—Doxorubicin—urinary bladder cancer	2.39e-05	0.000718	CcSEcCtD
Raltitrexed—Abdominal pain—Doxorubicin—urinary bladder cancer	2.39e-05	0.000718	CcSEcCtD
Raltitrexed—Diarrhoea—Methotrexate—urinary bladder cancer	2.39e-05	0.000718	CcSEcCtD
Raltitrexed—Asthenia—Epirubicin—urinary bladder cancer	2.35e-05	0.000704	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	2.33e-05	0.000789	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—TERT—urinary bladder cancer	2.33e-05	0.000788	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.33e-05	0.000786	CbGpPWpGaD
Raltitrexed—FPGS—Disease—RHOA—urinary bladder cancer	2.32e-05	0.000784	CbGpPWpGaD
Raltitrexed—Pruritus—Epirubicin—urinary bladder cancer	2.31e-05	0.000694	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.31e-05	0.00078	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—NAT2—urinary bladder cancer	2.3e-05	0.000778	CbGpPWpGaD
Raltitrexed—Diarrhoea—Epirubicin—urinary bladder cancer	2.24e-05	0.000672	CcSEcCtD
Raltitrexed—FPGS—Metabolism—PPARG—urinary bladder cancer	2.24e-05	0.000755	CbGpPWpGaD
Raltitrexed—Vomiting—Methotrexate—urinary bladder cancer	2.22e-05	0.000667	CcSEcCtD
Raltitrexed—Rash—Methotrexate—urinary bladder cancer	2.2e-05	0.000661	CcSEcCtD
Raltitrexed—Dermatitis—Methotrexate—urinary bladder cancer	2.2e-05	0.000661	CcSEcCtD
Raltitrexed—Headache—Methotrexate—urinary bladder cancer	2.19e-05	0.000657	CcSEcCtD
Raltitrexed—Asthenia—Doxorubicin—urinary bladder cancer	2.17e-05	0.000652	CcSEcCtD
Raltitrexed—FPGS—Metabolism—CREBBP—urinary bladder cancer	2.15e-05	0.000726	CbGpPWpGaD
Raltitrexed—FPGS—Disease—ERBB2—urinary bladder cancer	2.15e-05	0.000726	CbGpPWpGaD
Raltitrexed—Pruritus—Doxorubicin—urinary bladder cancer	2.14e-05	0.000643	CcSEcCtD
Raltitrexed—FPGS—Disease—PTGS2—urinary bladder cancer	2.1e-05	0.00071	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—ATM—urinary bladder cancer	2.1e-05	0.000708	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CDK4—urinary bladder cancer	2.09e-05	0.000705	CbGpPWpGaD
Raltitrexed—Vomiting—Epirubicin—urinary bladder cancer	2.08e-05	0.000624	CcSEcCtD
Raltitrexed—Nausea—Methotrexate—urinary bladder cancer	2.08e-05	0.000623	CcSEcCtD
Raltitrexed—Diarrhoea—Doxorubicin—urinary bladder cancer	2.07e-05	0.000621	CcSEcCtD
Raltitrexed—Rash—Epirubicin—urinary bladder cancer	2.06e-05	0.000619	CcSEcCtD
Raltitrexed—Dermatitis—Epirubicin—urinary bladder cancer	2.06e-05	0.000618	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.05e-05	0.000693	CbGpPWpGaD
Raltitrexed—Headache—Epirubicin—urinary bladder cancer	2.05e-05	0.000615	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle, Mitotic—RB1—urinary bladder cancer	2.03e-05	0.000686	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—RRM2—urinary bladder cancer	1.99e-05	0.000671	CbGpPWpGaD
Raltitrexed—TYMS—Circadian rythm related genes—TP53—urinary bladder cancer	1.97e-05	0.000665	CbGpPWpGaD
Raltitrexed—Nausea—Epirubicin—urinary bladder cancer	1.94e-05	0.000583	CcSEcCtD
Raltitrexed—Vomiting—Doxorubicin—urinary bladder cancer	1.92e-05	0.000577	CcSEcCtD
Raltitrexed—Rash—Doxorubicin—urinary bladder cancer	1.91e-05	0.000573	CcSEcCtD
Raltitrexed—Dermatitis—Doxorubicin—urinary bladder cancer	1.91e-05	0.000572	CcSEcCtD
Raltitrexed—Headache—Doxorubicin—urinary bladder cancer	1.9e-05	0.000569	CcSEcCtD
Raltitrexed—TYMS—Metabolism—HPGDS—urinary bladder cancer	1.84e-05	0.000622	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ENO2—urinary bladder cancer	1.84e-05	0.000622	CbGpPWpGaD
Raltitrexed—FPGS—Disease—CDKN1A—urinary bladder cancer	1.84e-05	0.00062	CbGpPWpGaD
Raltitrexed—FPGS—Disease—PTEN—urinary bladder cancer	1.83e-05	0.000619	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—RB1—urinary bladder cancer	1.81e-05	0.000613	CbGpPWpGaD
Raltitrexed—Nausea—Doxorubicin—urinary bladder cancer	1.8e-05	0.000539	CcSEcCtD
Raltitrexed—TYMS—Metabolism—GSTT1—urinary bladder cancer	1.78e-05	0.000603	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.78e-05	0.000603	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—PTGS2—urinary bladder cancer	1.76e-05	0.000594	CbGpPWpGaD
Raltitrexed—FPGS—Disease—EP300—urinary bladder cancer	1.75e-05	0.00059	CbGpPWpGaD
Raltitrexed—FPGS—Disease—SRC—urinary bladder cancer	1.7e-05	0.000574	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CDKN2A—urinary bladder cancer	1.6e-05	0.000539	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—PTEN—urinary bladder cancer	1.53e-05	0.000518	CbGpPWpGaD
Raltitrexed—FPGS—Disease—MYC—urinary bladder cancer	1.52e-05	0.000514	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.51e-05	0.000509	CbGpPWpGaD
Raltitrexed—FPGS—Disease—EGFR—urinary bladder cancer	1.49e-05	0.000503	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—NQO1—urinary bladder cancer	1.48e-05	0.000501	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—EP300—urinary bladder cancer	1.46e-05	0.000494	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.46e-05	0.000493	CbGpPWpGaD
Raltitrexed—FPGS—Disease—KRAS—urinary bladder cancer	1.41e-05	0.000475	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—EP300—urinary bladder cancer	1.39e-05	0.000469	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CCND1—urinary bladder cancer	1.35e-05	0.000455	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CDKN1A—urinary bladder cancer	1.3e-05	0.000441	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—EP300—urinary bladder cancer	1.24e-05	0.000419	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GSTP1—urinary bladder cancer	1.24e-05	0.000418	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—MYC—urinary bladder cancer	1.21e-05	0.000409	CbGpPWpGaD
Raltitrexed—FPGS—Disease—HRAS—urinary bladder cancer	1.2e-05	0.000404	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GSTM1—urinary bladder cancer	1.14e-05	0.000384	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—NCOR1—urinary bladder cancer	1.14e-05	0.000384	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GPX1—urinary bladder cancer	1.09e-05	0.000368	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—MYC—urinary bladder cancer	1.08e-05	0.000365	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ERCC2—urinary bladder cancer	1.07e-05	0.000361	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—MTHFR—urinary bladder cancer	1e-05	0.00034	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—TP53—urinary bladder cancer	8.88e-06	0.0003	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PPARG—urinary bladder cancer	8.15e-06	0.000275	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CREBBP—urinary bladder cancer	7.83e-06	0.000264	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PTGS2—urinary bladder cancer	6.41e-06	0.000217	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PTEN—urinary bladder cancer	5.59e-06	0.000189	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—EP300—urinary bladder cancer	5.33e-06	0.00018	CbGpPWpGaD
